CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 32 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $182,506 | +49.8% | 10,857 | +4.1% | 0.00% | 0.0% |
| Q3 2023 | $121,868 | -18.2% | 10,425 | -51.1% | 0.00% | -50.0% |
| Q2 2022 | $149,000 | -15.8% | 21,308 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $177,000 | +30.1% | 21,308 | +6.3% | 0.00% | 0.0% |
| Q4 2021 | $136,000 | +151.9% | 20,046 | -16.5% | 0.00% | -50.0% |
| Q1 2014 | $54,000 | -3.6% | 24,000 | -14.3% | 0.00% | 0.0% |
| Q4 2013 | $56,000 | -34.1% | 28,000 | 0.0% | 0.00% | -42.9% |
| Q3 2013 | $85,000 | – | 28,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 17,875,655 | $94,920,000 | 9.39% |
| TANAKA CAPITAL MANAGEMENT INC | 283,334 | $1,505,000 | 4.86% |
| GABLES CAPITAL MANAGEMENT INC. | 490,564 | $2,606,000 | 1.84% |
| MANGROVE PARTNERS IM, LLC | 2,508,838 | $13,322,000 | 1.61% |
| Broadfin Capital, LLC | 880,303 | $4,674,000 | 0.86% |
| Atom Investors LP | 1,012,355 | $5,376,000 | 0.37% |
| Capital Impact Advisors, LLC | 179,868 | $948,000 | 0.36% |
| KNOTT DAVID M | 151,415 | $804,000 | 0.34% |
| EMERALD ADVISERS, LLC | 1,175,958 | $6,244,000 | 0.29% |
| CADENCE CAPITAL MANAGEMENT LLC | 371,075 | $1,970,000 | 0.28% |